Oncocyte Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Years Ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Net loss | $(27,781) | $(72,902) |
| Foreign currency translation adjustments | 10 | 2 |
| Comprehensive loss | $(27,771) | $(72,900) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.